– USA, MA – Algorics Inc., one of the fastest-growing biometrics and data science companies, today announced the addition of Alan Morgan to its Board of Directors.
The company also announced the appointments of Greg Steffens as Strategic Advisor and Stephen Boccardo as SVP for Business Development and Commercial Strategy.
“Each of these individuals brings a wealth of experience and insight that will be invaluable as Algorics continues to evolve and grow. Their deep industry knowledge and leadership will be critical as we work towards our strategic objectives,” said Founder and CEO, Nithiya Ananthakrishnan.
About Alan Morgan
Alan Morgan is an experienced and highly accomplished professional in the life sciences industry. Over the last 30 years, he has held various leadership positions within CROs, having started his career with AstraZeneca and GSK. His career highlights include leadership positions at ICON, Covance, Excelya, Quanticate, MDS (now Syneos Health), RPS (now PRA/ICON), and Gentronix.
Alan Morgan said “It’s been a pleasure to watch Algorics grow over the years to become one of the leading clinical data science organizations. I look forward to contributing to the company’s continued success in delivering clinical data excellence, for life sciences customers globally.”
About Greg Steffens
Greg Steffens has been an industry stalwart utilizing SAS for programming and application development since 1981. Throughout his career, he has played a key role in CDISC initiatives. He has held various roles, ranging from lead technical positions to leadership roles, and spearheaded automation initiatives in various pharmaceutical companies. His expertise encompasses the creation and implementation of metadata-driven solutions to streamline tasks such as data definition, data transformation, data validation, and FDA submissions.
About Stephen Boccardo
Stephen Boccardo is a seasoned commercial expert with over 30 years of experience in building and managing large commercial organizations with key industry players such as Liquent (now Parexel), BioClinica, Clinical Ink, and Quartesian. As an expert in clinical data and biometrics businesses, Stephen will be leading business development and commercial strategy at Algorics.
About Algorics
Founded in 2013, Algorics is a specialized data sciences partner to the life sciences industry focusing on data management, biostatistics, statistical programming, and data standardization. The company supports a global portfolio of biopharmaceutical and CRO clients with cost-effective and high-quality data services underpinned by technology know-how and access to talent across US, Europe, and Asia. We help our customers increase productivity and accelerate development with our technology-backed solutions to enable data standardization and faster statistical reporting.
SOURCE: https://algorics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.